A phase I/II trial adding the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib to induction carboplatin-paclitaxel in patients with locoregionally advanced squamous cell carcinoma of the head and neck (HNSCC) Alliance A091101
      Google Scholar   
Citation:
J Clin Oncol vol 36 (15 suppl) 6031
Meeting Instance:
ASCO 2018
Year:
2018
Type:
Abstract
Sub type:
Poster Discussion
Funding:
NCTN
Endpoint:
Primary
Analysis:
Preliminary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
epub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Parents:
None
Children:
3382  
Program:
OGC
Primary Committee:
Experimental
Sec. Committees:
   
Pharmas:
 
Grants:
U10CA180821, U10CA180882  
Corr. Author:
 
Authors:
                 
Networks:
CA824, COLUMBIA, IL043, LAPS-IL057, LAPS-MD017, LAPS-MN026   
Study
Alliance-A091101
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
1/2
Keywords: